Exosome Bioactivity & Potency Assessment

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide comprehensive bioactivity and potency assessment services purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), cytoplasmic membrane vesicles (CMVs) from Gram-positive bacteria, fungal EVs, and phage-derived vesicles. Our platform integrates immunomodulatory screening, cell migration and invasion assays, enzymatic activity profiling, anti-inflammatory and antioxidant evaluation, and cytotoxicity testing into a single, standardized workflow that quantifies the functional potency of vesicle preparations and validates their biological activity for therapeutic, vaccine, probiotic, and cosmetic applications.

Unlike generic cell assay CROs that apply mammalian exosome bioactivity protocols to microbial samples, we have optimized every cell model, dosing parameter, and readout criterion for the unique surface properties, cargo composition, and host-interaction mechanisms of mEVs. From purified vesicle suspension to publication-ready potency report, clients receive validated bioactivity endpoints, dose-response curves, and mechanism-of-action data that support product potency claims, CMC documentation, lot-release specifications, and regulatory submissions. Contact us to discuss your specific bioactivity testing and potency assessment requirements.

Scientific schematic of integrated bioactivity and potency assessment platform for microbial extracellular vesicles, showing immunomodulatory screening, cell migration/invasion assays, enzymatic activity profiling, anti-inflammatory/antioxidant evaluation, and cytotoxicity testing modules.
Figure 1. Schematic overview of the integrated bioactivity and potency assessment platform for microbial extracellular vesicles, spanning immunomodulatory screening, cell migration and invasion assays, enzymatic activity profiling, anti-inflammatory and antioxidant evaluation, and cytotoxicity testing.

Services

Service Workflow

Commercial end-to-end service workflow diagram for bioactivity and potency assessment showing seven stages from sample inquiry through sample receipt, vesicle dosing, bioactivity screening, dose-response analysis, mechanistic validation, potency ranking, and final report delivery.

Inquiry

Service Details

Split-screen comparison illustration showing T cell proliferation inhibition on one side with CFSE dilution flow cytometry plots, and cytokine profiling on the other side with ELISA microplate wells and multiplex bead array readout.

Immunomodulatory Screening (T Cell Proliferation & Cytokine Profiling)

We evaluate the immunomodulatory potency of mEVs using primary human T cell proliferation assays and multiplex cytokine profiling. Proliferation inhibition is quantified by flow cytometry, while cytokine profiling measures IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α using Luminex multiplex bead arrays or ELISA. Macrophage polarization studies assess M1/M2 surface markers (CD80, CD86, CD206, CD163) by flow cytometry. This service validates immunomodulatory claims for probiotic, vaccine, and therapeutic mEV products.

Process flow illustration showing a Transwell migration assay with cells migrating through porous membrane toward chemoattractant, followed by crystal violet staining and quantification.

Cell Migration & Invasion Assays

We assess the effect of mEVs on cell migration and invasion using Transwell and Matrigel-coated invasion chamber assays. Migration is quantified by crystal violet staining and absorbance measurement, while invasion is evaluated through Matrigel-coated chambers simulating extracellular matrix degradation. Wound healing (scratch) assays provide complementary 2D migration kinetics. Results include migration/invasion indices, wound closure percentages, and MMP activity correlation for anti-metastatic, wound-healing, and barrier-repair applications.

Molecular close-up illustration showing microbial vesicle-associated enzymes including proteases, lipases, and esterases acting on fluorescent substrate molecules, with colorimetric and fluorometric readout signals.

Enzymatic Activity Profiling

We measure enzymatic activity within mEV cargo using fluorometric and colorimetric substrate assays. Our standard panel includes proteases, lipases/esterases, phosphatases, and glycosidases, with custom assays available for OMV-associated virulence enzymes. Activity is expressed as specific activity (units/mg protein), dose-response curves, and Michaelis-Menten kinetics (K_m, V_max) where applicable. This service predicts functional potency, validates cargo integrity after storage or processing, and identifies bioactive enzyme candidates.

Biological cross-section illustration showing a macrophage cell with internalized microbial vesicles, suppressed NF-kB signaling pathway, reduced ROS production, and elevated IL-10 secretion visualized as molecular signaling cascades.

Anti-Inflammatory & Antioxidant Evaluation

We evaluate anti-inflammatory and antioxidant bioactivity using LPS-stimulated macrophage models and primary human PBMCs. Anti-inflammatory potency is measured by TNF-α, IL-1β, and IL-6 suppression, quantified by ELISA or multiplex cytokine arrays. NF-κB reporter assays provide mechanistic pathway data. Antioxidant activity is assessed using DCFH-DA (intracellular ROS), DHE (superoxide), and lipid peroxidation (MDA assay). Results include IC₅₀ values, ROS reduction percentages, and NF-κB inhibition dose-response curves.

Abstract data visualization showing a 96-well plate heat map with cell viability percentages across multiple vesicle concentrations and cell types, with dose-response curves and IC50 determination plots.

Cytotoxicity & Biocompatibility Safety Profiling

We assess cytotoxicity and biocompatibility using MTT, resazurin (Alamar Blue), and LDH release assays across HEK293, Caco-2, HaCaT, and primary human dermal fibroblasts. Dose-response curves determine the no-observed-adverse-effect level (NOAEL) and half-maximal cytotoxic concentration (CC₅₀). Hemolysis assays evaluate membrane-disruptive potential, and reconstructed human epidermis (RhE) irritation testing supports cosmetic and topical applications. Results include viability heat maps, CC₅₀/NOAEL values, hemolysis percentages, and RhE tissue viability scores.

Service Specifications & QC Standards

Typical Data Range

T cell proliferation inhibition: 10–80% (vesicle and concentration dependent).
Cytokine detection: 0.1–10,000 pg/mL sensitivity (Luminex); 1.5–2,000 pg/mL (ELISA).
Migration index: 0.1–3.0-fold change vs. vehicle control.
Enzymatic activity: 0.01–100 U/mg protein (substrate dependent).
Anti-inflammatory IC₅₀: 10⁷–10¹⁰ particles/mL (strain dependent).
ROS reduction: 10–70% decrease vs. LPS control.
Cell viability CC₅₀: typically >10¹¹ particles/mL for non-toxic mEVs.

Turnaround Time

Project Type	Timeline
T cell proliferation only	7–10 business days
Cytokine profiling (multiplex)	5–7 business days
Migration/invasion assay	7–10 business days
Enzymatic activity profiling	3–5 business days
Anti-inflammatory/antioxidant panel	7–10 business days
Cytotoxicity/biocompatibility	5–7 business days
Standard potency package (all assays)	21–28 business days
Expedited analysis	+50% fee, 50% time reduction

Timeline may vary based on cell model availability, vesicle type, and assay complexity.

Deliverables

Immunomodulatory: T cell proliferation histograms, cytokine concentration tables, M1/M2 polarization flow plots.
Migration/Invasion: Migration/invasion indices, wound closure images, quantitative absorbance data.
Enzymatic: Specific activity values, dose-response curves, kinetic parameters (K_m, V_max).
Anti-inflammatory/antioxidant: IC₅₀ values, ROS reduction data, NF-κB inhibition curves, Western blot images.
Cytotoxicity: Viability heat maps, CC₅₀/NOAEL values, hemolysis percentages, RhE viability scores.
Integrated potency report: Cross-assay potency ranking, statistical analysis, QC flags.

Quality Control

Positive controls: Dexamethasone (anti-inflammatory), mitomycin C (T cell suppression), LPS (pro-inflammatory stimulus).
Negative controls: Vehicle-only (PBS), heat-inactivated vesicles, vesicle-depleted supernatant.
Cell viability validation: ≥ 95% viability for untreated controls at assay start.
Intra-assay CV ≤ 15%; inter-assay CV ≤ 20% for all quantitative endpoints.
Dose-response curve quality: R² ≥ 0.90 for IC₅₀/CC₅₀ determination.
LPS contamination check: Limulus amebocyte lysate (LAL) assay on all vesicle preparations to exclude endotoxin-driven artifacts.
Compliance checklist for minimal characterization requirements aligned with industry guidelines for extracellular vesicle studies.
Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.

Sample Requirements

Required Information	Optional Information	Not Accepted
Sample type (OMVs, CMVs, fungal EVs, phage vesicles) Purified vesicle suspension Approximate particle concentration (NTA data preferred) Sample volume (minimum 200 μL for standard panel) Buffer composition and pH Species/strain identification Storage conditions and shipping temperature	Prior bioactivity data or literature references Specific bioactivity hypothesis (anti-inflammatory, immunosuppressive, etc.) Target cell type or tissue of interest Reference batch for comparative potency Regulatory documentation requirements	Samples with visible aggregation or precipitation Samples in fixatives or organic solvents Samples without proper cold-chain documentation Intact bacterial/fungal cell cultures Contaminated or mixed samples Samples shipped at room temperature

Recommended Sample Quantity by Assay:

Assay	Minimum Volume	Recommended Volume
T cell proliferation	200 μL	500 μL
Cytokine profiling	50 μL	100 μL
Migration/invasion	100 μL	200 μL
Enzymatic activity	50 μL	100 μL
Anti-inflammatory/antioxidant	100 μL	200 μL
Cytotoxicity	50 μL	100 μL
Standard potency package	300 μL	600 μL

Storage & Shipping: Ship purified vesicle suspensions on dry ice (–80°C) or wet ice (4°C) with cold-chain documentation. Avoid repeated freeze-thaw cycles. Recommended buffer: sterile PBS. For enzymatic activity assays, avoid buffers containing protease inhibitors or EDTA. Provide NTA-derived particle concentration if available.

Inquiry

Our Advantages

Microbial EV-Specific Bioactivity Panels: Our immunomodulatory, anti-inflammatory, and enzymatic assays are calibrated against microbial vesicle matrices. We perform LAL endotoxin testing on every vesicle preparation to exclude LPS-driven artifacts that confound bioactivity interpretation for Gram-negative OMVs.
Multi-Endpoint Potency Profiling: We assess bioactivity across multiple orthogonal endpoints (cytokine suppression, T cell inhibition, ROS reduction, enzyme activity) under standardized conditions, providing a comprehensive potency profile that single-endpoint assays cannot deliver.
Mechanistic Insight Integration: Our NF-κB reporter assays, TLR pathway inhibitor panels, and macrophage polarization studies connect bioactivity readouts to molecular mechanisms, enabling rational product engineering and supporting intellectual property claims.
Comparative Potency Ranking: We offer head-to-head potency comparisons across multiple vesicle preparations, strains, purification methods, or production batches, with statistical ranking and equivalence testing for lot-release and CMC documentation.
Safety-Bioactivity Coupled Assessment: Our standard workflow integrates cytotoxicity and hemolysis testing alongside bioactivity profiling, ensuring that potency claims are supported by safety data and that the therapeutic window is clearly defined.

Applications

Vaccine adjuvant OMV potency lot-release application showing central OMV particle surrounded by immunostimulatory activity modules including dendritic cell activation, cytokine induction, and T cell proliferation with potency specification checkmarks.

OMV Vaccine Adjuvant Potency & Lot-Release

Immunostimulatory potency assays validate OMV vaccine lot consistency and support regulatory lot-release specifications.

Probiotic mEV anti-inflammatory validation application showing left-to-right workflow from probiotic vesicle treatment through macrophage cytokine suppression to reduced inflammation in intestinal tissue.

Probiotic mEV Anti-Inflammatory Validation

TNF-alpha suppression and IL-10 induction assays validate anti-inflammatory potency of probiotic-derived vesicle products.

Therapeutic mEV safety-potency window application showing top-to-bottom cascade from cytotoxicity safety threshold through bioactivity dose-response to optimal therapeutic dosing range.

Therapeutic mEV Safety-Potency Window

Coupled cytotoxicity and bioactivity profiling defines the therapeutic window for clinical mEV candidates.

Cosmetic mEV antioxidant and irritation safety application showing scale transition from macroscopic skin application to microscopic keratinocyte ROS reduction and RhE tissue viability testing.

Cosmetic mEV Antioxidant & Irritation Safety

Antioxidant potency and RhE irritation testing validate cosmetic vesicle actives for safety and efficacy claims.

Case Study

Case Study: Anti-Inflammatory Potency of Bacteroides thetaiotaomicron-Derived Extracellular Vesicles

Bacteroides thetaiotaomicron is a dominant human gut commensal bacterium whose extracellular vesicles (BEVs) modulate host immune responses. Researchers systematically assessed the anti-inflammatory bioactivity of B. thetaiotaomicron BEVs using both in vitro and in vivo potency assays to define their immunomodulatory mechanism and therapeutic potential.

In vitro, BEV treatment of bone marrow-derived macrophages significantly upregulated IL-10 secretion while suppressing TNF-α production, with potency confirmed via THP1-Blue NF-κB reporter assays showing TLR2-dependent signaling. Epigenetic analysis revealed H3K4me1 histone methylation changes consistent with innate immune cell reprogramming toward a tolerogenic phenotype. In vivo, BEV administration in a DSS-induced acute colitis mouse model improved survival, reduced weight loss, and decreased disease activity index, correlating with elevated IL-10 levels in colonic tissue and splenocytes. This study demonstrates how integrated in vitro and in vivo bioactivity assessment can validate the anti-inflammatory potency of microbial EVs and elucidate their mechanism of action.

Figure 2. Bt BEVs modulate the production of anti- and pro-inflammatory cytokines by murine bone marrow derived macrophages (BMDM). (Fonseca, et al. 2022)

FAQs

Q: How do you distinguish true anti-inflammatory activity from endotoxin artifacts?

A: We perform LAL endotoxin testing on every vesicle preparation. For Gram-negative OMVs, we include heat-inactivated vesicle controls (which denature proteins but retain LPS) and LPS-neutralizing antibody (polymyxin B) controls to separate protein-mediated bioactivity from endotoxin-driven effects. If endotoxin levels exceed 0.05 EU/mL, we flag the result and recommend additional controls.

Q: Can you test mEVs on primary human cells?

A: Yes. We offer bioactivity testing on primary human PBMCs, primary T cells (isolated from donor blood), primary human dermal fibroblasts, and primary keratinocytes. For PBMC and T cell assays, we require donor material with appropriate consent documentation. Cell isolation and characterization are included in the service fee.

Q: What is the difference between potency and bioactivity?

A: Bioactivity refers to any measurable biological effect (e.g., cytokine modulation, enzyme activity). Potency is the quantitative measure of that bioactivity under standardized conditions, expressed as an IC₅₀, EC₅₀, or relative potency unit. Potency data supports lot-release specifications and regulatory submissions, while bioactivity data supports research publications and mechanism-of-action studies.

Q: Can you compare potency across different production batches?

A: Yes. We offer comparative potency analysis that profiles multiple batches side-by-side under identical assay conditions. Statistical comparison includes ANOVA with post-hoc testing, equivalence margins (e.g., 80–125% relative potency), and control chart trending for ongoing batch monitoring.

Q: How do you measure enzymatic activity within vesicles vs. released enzymes?

A: We measure total vesicle-associated enzymatic activity (intact vesicles) and compare with supernatant after ultracentrifugation (released/free enzymes). The vesicle-associated fraction represents cargo integrity, while the free fraction indicates enzyme leakage during storage or processing. This distinction is critical for product stability assessment.

Q: What cell models do you use for anti-inflammatory testing?

A: Our standard anti-inflammatory panel uses LPS-stimulated RAW 264.7 murine macrophages and LPS-stimulated THP-1 human macrophages. For translational studies, we offer primary human PBMC assays. NF-κB reporter assays use hTLR2 and hTLR4 cells to dissect TLR-dependent signaling. Cell model selection depends on the target application and regulatory requirements.

Q: Do you offer in vivo bioactivity testing?

A: Our standard service is in vitro only. In vivo efficacy studies (mouse colitis models, tumor models, skin inflammation models) are available through partner CRO networks and require additional ethics and regulatory documentation. Contact us to discuss in vivo study design and coordination.

Q: Is your bioactivity assay service compatible with GxP requirements?

A: Our standard service is research-grade (R&D) with validated methods and full QC documentation. GxP-aligned potency assay validation (per ICH Q2(R1) and ICH Q6B guidelines), including accuracy, precision, specificity, linearity, and robustness, is available as a custom service. Contact us to discuss your regulatory pathway requirements.

References:

Fonseca, S., et al. (2022). Extracellular vesicles produced by the human gut commensal bacterium Bacteroides thetaiotaomicron elicit anti-inflammatory responses from innate immune cells. Frontiers in Microbiology, 13, 1050271.

Services

Inquiry